Living with HIV requires consistent treatment to keep the virus suppressed. A recent trial looked at a new daily pill option for people who already have their virus well controlled. The study tested a switch from a three-drug regimen to a two-drug combination of bictegravir and lenacapavir.
Researchers followed 574 people across 100 hospitals and clinics. At the end of 48 weeks, both groups performed very similarly in keeping the virus levels low. In the new pill group, only 1.3% had high virus levels, while 1.0% had high levels in the current treatment group. The difference between the two was very small.
Safety data showed that both treatments were well tolerated. While some people experienced drug-related issues, the number of serious events was similar across both groups and none were linked to the medication itself. This new combination could offer a simpler daily routine for those seeking a different treatment path.
Common questions
How does this new medication compare to current treatments?
The study found that the new two-drug combination (bictegravir and lenacapavir) worked very similarly to the current three-drug treatment. At 48 weeks, only 1.3% of people on the new pill had high virus levels, compared to 1.0% on the standard treatment. The difference between the two options was small.
Is the new daily pill safe for people with HIV?
The trial included 574 people and showed that both treatments were manageable. While about 10% of people on the new pill had drug-related events, the number of serious issues was similar in both groups (7%). None of these serious events were caused by the medication itself.
Who is eligible for this new treatment option?
This specific study focused on people with HIV-1 who already have their virus suppressed. Because every person's health needs are different, you should talk to your doctor to see if a switch to a two-drug regimen like bictegravir and lenacapavir is right for you.
